Perrigo plant workers strike; China's Harbin moves odorous plant;

> About 350 workers at a Perrigo ($PRGO) plant in the Bronx borough of New York City have gone on strike after being locked out after a breakdown in negotiations over a new contract. Story

> A consortium of Hermes Pharma, Research Center Pharmaceutical Engineering GmbH (RCPE), INNOJET Herbert Hüttlin and the Karl Franzens University has been created to develop new formulations and manufacturing processes that can be used to mask bad tastes and odors associated with some APIs. Release

> The FDA announced that as part of the new program to collect user fees from generic drugmakers, it "will aim to achieve risk-adjusted biennial inspections and parity of inspection coverage between foreign and domestic firms in five years." Release

> To aid an expansion in developing countries, Sproxil has nailed down a deal with mobile giant Bharti Airtel that allows it to expand its mobile system for authenticating drugs to 17 countries in Africa where Bharti provides wireless service. Story

> South Carolina-based American BioTech Supply has donated four new vaccine refrigerators to Denver Health, a Colorado safety-net healthcare organization. Item

> Sigma-Aldrich ($SIAL) has an agreement to distribute mass spectrometry-based tagging chemistries from AB SCIEX. Release

And Finally... Chinese drugmaker Harbin Pharmaceutical Group, which has been battling with neighbors about odors from its plant in downtown Harbin, has started construction on a new $110 million plant on the outskirts of town. Story

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.